scispace - formally typeset
Journal ArticleDOI

Anti-cancer drugs

Elke S. Bergmann-Leitner
- 31 Mar 2005 - 
- Vol. 14, Iss: 11, pp 1048-1048
Reads0
Chats0
About
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.

read more

Citations
More filters
Journal ArticleDOI

The status of platinum anticancer drugs in the clinic and in clinical trials.

TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI

Natural products to drugs: natural product derived compounds in clinical trials

TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI

Cellular distribution and functions of P2 receptor subtypes in different systems.

TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI

Natural products: an evolving role in future drug discovery.

TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
References
More filters
Journal ArticleDOI

The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro

TL;DR: In vitro studies can be useful to develop feasible strategies to mitigate the side-effects of Pt-based anticancer drugs in patients, and the observed amelioration of the side effects of CP by STS can be rationalized in terms of the rapid formation of a biologically inactive Pt-STS complex in the bloodstream.
Journal ArticleDOI

Gefitinib: an adverse effects profile.

TL;DR: The most severe adverse effect is interstitial lung disease (ILD), which occurs in ∼ 1% of patients worldwide except for Japan where the incidence of ILD is 2%.
Journal ArticleDOI

Ruthenium(II)/chiral Brønsted acid co-catalyzed enantioselective four-component reaction/cascade aza-Michael addition for efficient construction of 1,3,4-tetrasubstituted tetrahydroisoquinolines

TL;DR: An elegant synergistic catalytic system comprising a ruthenium complex with a chiral Brønsted acid was developed for a four-component Mannich/cascade aza-Michael reaction, featuring a mild, rapid, and efficient method for the synthesis of enantiomerically pure tetrahydroquinolines bearing a quaternary stereogenic carbon center from simple starting precursors in moderate yields with high diastereo- and enantioselectivity.
Journal ArticleDOI

Combination of vascular disrupting agents and ionizing radiation.

TL;DR: There is a lack of clinical trials evaluating such combinations of VDA and chemotherapeutic agents, whereas it would be of great interest since radiotherapy is widely used as anticancer treatment.
Journal ArticleDOI

Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.

TL;DR: Several derivatives of combretastatin have been prepared bearing a cyclopropyl unit instead of the natural occurring cis-double bond and these products and synthetic intermediates were evaluated for their cytotoxic properties in two human cancer cell lines.